Comparing a biosimilar to Keytruda for melanoma after surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a biosimilar drug (AVT32-DRL_PB) to see how it compares to the approved immunotherapy Keytruda® in people whose melanoma has been fully removed by surgery. It aims to help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need to be able to carry out daily activities with little to no help (ECOG 0 or 1).
- Your melanoma must be stage IIB, IIC, or III and confirmed as skin (cutaneous) melanoma.
- You cannot have had any previous cancer treatment for melanoma, including experimental drugs.
- You cannot have had an organ or stem cell transplant using donor cells.
- You cannot have melanoma that started in your mouth, nose, or eye (mucosal or uveal melanoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new biosimilar drug (Bmab1700) works as well as the approved immunotherapy Opdivo (nivolumab) to prevent melanoma from coming back after surgery. You would receive either the biosimilar or Opdivo for about a year, and researchers will compare how your body handles the drug and its safety.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests whether giving a combination of three immunotherapy drugs before surgery can help shrink melanoma and improve outcomes. It is for people whose melanoma can be surgically removed, and the goal is to see if this approach is safe and effective.
This trial tests whether giving two drugs (QL1706 and OH2) before and after surgery can help treat stage III acral melanoma, a type of skin cancer on the palms, soles, or under nails. The goal is to see if this approach reduces the chance of the cancer coming back.
This study compares two immunotherapy drugs to see which is better at preventing melanoma from returning after surgery. One drug is an experimental biosimilar similar to Keytruda, and the other is Keytruda itself.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.